Eos Energy Enterprises Inc vs Zoetis Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.26 (market cap $1.54B), while Zoetis Inc trades at $73.53 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 20.2× Eos Energy Enterprises Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | ZTS | |
|---|---|---|
Market Cap | $1.54B | $31.14B |
Sector | Energy | Health |
52-Week High | $19.19 | $156.76 |
52-Week Low | $3.14 | $71.91 |
Enterprise Value | $1.88B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.24, up 4.69% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 loss per share. Financials reveal significant challenges with negative gross margins of -84.75% and net income margin of -246.76% for 2026, though revenue growth from $114M to $214M year-over-year shows scaling progress.
While analyst consensus targets $7.75 (83% upside), the stock faces substantial fundamental risks including negative profitability, shareholder litigation investigation, and high debt-to-asset ratio of 91.87%. The company's energy storage technology and growing backlog provide potential, but execution risks and cash burn require careful monitoring for investors considering this speculative growth play.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →